Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITOP1 vaccine trial in resectable oesophageal adenocarcinoma
ISRCTN12981444Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 2, randomised trial in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma comparing Phase I safety lead-in ITOP1, Phase II ITOP1 plus standard of care and Phase II placebo plus standard of care (3 arms). Primary endpoint: Safety and tolerability of ITOP1. Started Nov 2025; status: active, not recruiting.
02
Drugs
ITOP1
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ISRCTN12981444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12981444.